Literature DB >> 11553783

Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.

B Kwabi-Addo1, D Giri, K Schmidt, K Podsypanina, R Parsons, N Greenberg, M Ittmann.   

Abstract

The PTEN gene encodes a lipid phosphatase that negatively regulates the phosphatidylinositol 3-kinase pathway and is inactivated in a wide variety of malignant neoplasms. High rates of loss of heterozygosity are observed at the 10q23.3 region containing the human PTEN gene in prostate cancer and other human malignancies, but the demonstrated rate of biallelic inactivation of the PTEN gene by mutation or homozygous deletion is significantly lower than the rate of loss of heterozygosity. The transgenic adenocarcinoma of mouse prostate model is a well characterized animal model of prostate cancer. Analysis of prostate cancer progression in transgenic adenocarcinoma of mouse prostate mice bred to Pten(+/-) heterozygous mice, coupled with analysis of the Pten gene and protein in the resulting tumors, reveals that haploinsufficiency of the Pten gene promotes the progression of prostate cancer in this model system. This observation provides a potential explanation for the discordance in rates of loss of heterozygosity at 10q23 and biallelic PTEN inactivation observed in prostate cancer and many human malignancies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553783      PMCID: PMC58769          DOI: 10.1073/pnas.201167798

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  The multiple roles of PTEN in tumor suppression.

Authors:  A Di Cristofano; P P Pandolfi
Journal:  Cell       Date:  2000-02-18       Impact factor: 41.582

2.  Pten, a candidate tumor suppressor gene, maps to mouse chromosome 19.

Authors:  G M Hansen; M J Justice
Journal:  Mamm Genome       Date:  1998-01       Impact factor: 2.957

3.  Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma.

Authors:  D Giri; M Ittmann
Journal:  Hum Pathol       Date:  1999-04       Impact factor: 3.466

4.  Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.

Authors:  K Kurose; X P Zhou; T Araki; S A Cannistra; E R Maher; C Eng
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

6.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.

Authors:  S I Wang; R Parsons; M Ittmann
Journal:  Clin Cancer Res       Date:  1998-03       Impact factor: 12.531

7.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

Authors:  A Perren; L P Weng; A H Boag; U Ziebold; K Thakore; P L Dahia; P Komminoth; J A Lees; L M Mulligan; G L Mutter; C Eng
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

8.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

10.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

View more
  104 in total

1.  Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.

Authors:  Hong Shen-Li; Susan Koujak; Matthias Szablocs; Ramon Parsons
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

2.  Mapping a diversity of genetic interactions in yeast.

Authors:  Jolanda van Leeuwen; Charles Boone; Brenda J Andrews
Journal:  Curr Opin Syst Biol       Date:  2017-08-12

3.  Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation.

Authors:  Fumiaki Okahara; Kouichi Itoh; Akira Nakagawara; Makoto Murakami; Yasunori Kanaho; Tomohiko Maehama
Journal:  Mol Biol Cell       Date:  2006-09-13       Impact factor: 4.138

4.  Haploinsufficiency in multiploid colorectal cancer.

Authors:  Minoru Toyota; Kohzoh Imai; Yasuhisa Shinomura
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

5.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

6.  Chromatin PTEN is involved in DNA damage response partly through regulating Rad52 sumoylation.

Authors:  Byeong Hyeok Choi; Yan Chen; Wei Dai
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

7.  The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

Authors:  Yulan Sun; Daret K St Clair; Fang Fang; Graham W Warren; Vivek M Rangnekar; Peter A Crooks; William H St Clair
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

Review 8.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

9.  Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells.

Authors:  Loren Michel; Elena Diaz-Rodriguez; Gopeshwar Narayan; Eva Hernando; Vundavalli V V S Murty; Robert Benezra
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

10.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.